Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12222421 | PMC |
| http://dx.doi.org/10.1245/s10434-025-17534-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ASO Author Reflections: Overcoming Clinical Barriers and Realizing Reciprocal Benefits of Multidisciplinary Conferences.
Ann Surg Oncol
September 2025
St. Paul's Hospital, The University of British Columbia, Vancouver, Canada.
ASO Author Reflections: Central Hepatectomy for Perihilar Cholangiocarcinoma: A Tailored Alternative to Conventional Major Hepatectomy.
Ann Surg Oncol
September 2025
Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan.
ASO Author Reflections: Outcome-Based Referrals for Parathyroidectomy may be the Future of Care for Patients with Primary Hyperparathyroidism.
Ann Surg Oncol
September 2025
Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, USA.
ASO Author Reflections: Cone Unit Liver Resection: Innovation or Overcomplication?
Ann Surg Oncol
September 2025
Carle Illinois College of Medicine University of Illinois Urbana-Champaign, Urbana, IL, USA.
Prognostic factors of lenvatinib plus pembrolizumab therapy for advanced or recurrent endometrial cancer: analysis of a multicenter cohort study in Japan.
Int J Clin Oncol
September 2025
Department of Obstetrics and Gynecology, The University of Osaka Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Background: Lenvatinib plus pembrolizumab (LP) therapy has emerged as an effective treatment for patients with advanced or recurrent endometrial cancer. However, limited data are available regarding its outcomes in real-world settings. This study aimed to identify prognostic factors associated with the efficacy of LP therapy.
View Article and Find Full Text PDF